Monitor for partnering or financing announcements given the $6.4M cash runway into 2027 and the company's statement that further development of CM24 and NT219 requires partnering or additional investment. The CAPTN-3 platform's preclinical data and AI collaboration are key catalysts to watch for IND filings and clinical trial initiations.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 15 $3.94entry
- T+1 · 6mo ago −4.06%α −4.00% · $3.78
- T+5 · 6mo ago −26.90%α −27.87% · $2.88
- T+20 · 5mo ago −57.11%α −59.23% · $1.69
- T+60 · 3mo ago −60.66%α −65.18% · $1.55
Price Chart
How similar events traded
Executive Summary
Purple Biotech reported Q1 2026 net loss of $0.1M, significantly narrower than the $0.5M loss in Q1 2025, driven by $2.2M in non-cash finance income from warrant revaluation. The company had $6.4M in cash as of March 31, 2026, expected to fund operations into 2027. The press release focused on preclinical data for its CAPTN-3 platform and IM1240 tri-specific antibody, with no revenue reported.
Key Financial Metrics
Key Facts
- Net loss of $0.1M for Q1 2026 vs $0.5M in Q1 2025, improvement driven by $2.2M non-cash finance income from warrant fair value changes
- Adjusted operating loss (non-IFRS) was $2.1M, up from $1.3M in Q1 2025
- Cash and cash equivalents and short-term deposits of $6.4M as of March 31, 2026, expected to provide runway into 2027
- No revenue reported; company is clinical-stage with no approved products
- Lead program CAPTN-3 (IM1240) advancing toward first-in-human studies in 2027
- Expanded collaboration with Converge Bio for generative AI-driven antibody design
- Established CAPTN-3 Scientific Advisory Board
Financial Impact
Cash burn of $3.1M in operating cash flow during Q1 2026; $6.4M cash position provides runway into 2027
Risk Factors
- Cash runway limited to 2027; additional financing likely needed before reaching profitability
- Preclinical-stage pipeline with no approved products; high clinical development risk
- Dependence on successful partnering for legacy assets CM24 and NT219
- Net loss improvement driven by non-cash finance income, not operational improvement
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295734 |
Track record
14 reports on PPBT
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago SC 13G Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
- Nov 12, 20265d ago EFFECT Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $1.49 Now $1.68 +12.75% settles Feb 9
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $1.09 Now $1.68 +54.13% settles Jan 27
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $1.47 Now $1.68 +14.29% settles Dec 31
- Sep 9, 20269w ago 6-K Neutral 2/10 Entry $1.74 Now $1.68 −3.45% settles Dec 4
- Sep 2, 202610w ago 6-K Neutral 3/10 Entry $1.98 Now $1.68 −15.15% settles Nov 27
- Aug 10, 202614w ago 6-K Neutral 4/10 Entry $1.55 to $1.22 Now $1.68 +8.39% ▼ −21.61% −21.13% vs SPY
- Aug 7, 202614w ago 6-K Neutral 4/10 Entry $1.43 to $1.22 Now $1.68 +17.48% ▼ −14.69% −12.55% vs SPY
- May 15, 202626w ago Press Release Neutral 4/10 Viewing Entry $3.94 to $1.55 Now $1.68 −57.36% ▼ −60.66% −65.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers